| Nov 9 |
Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...
|
| Nov 8 |
Y-mAbs Therapeutics, Inc. (YMAB) Q3 2024 Earnings Call Transcript
|
| Nov 8 |
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
|
| Nov 8 |
Y-mAbs Therapeutics GAAP EPS of -$0.16 beats by $0.01, revenue of $18.46M misses by $4.8M
|
| Nov 8 |
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
|
| Nov 5 |
Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?
|
| Nov 4 |
Y-mAbs and Nobelpharma sign license and distribution agreement for DANYELZA in Japan
|
| Nov 4 |
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan
|
| Nov 1 |
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know
|
| Oct 25 |
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
|
